ISBT BOOST VS IMRT BOOST IN CERVICAL CANCER PATIENTS

A PILOT STUDY OF INTERSTITIAL BOOST BRACHYTHERAPY VS INTENSITY MODULATED RADIOTHERAPY BOOST IN PATIENTS WHO ARE UNSUITABLE FOR CONVENTIONAL BRACHYTHERAPY IN CERVICAL CANCER

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048293

Enrollment

Registered

2022-12-20

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Interstitial Brachytherapy Boost: A boost by Interstitial brachytherapy 5.72Gy/4#(2# per day, 6 hrs apart- total of 2 days) will be given to patients in 1st arm after External beam radi

Eligibility

Inclusion criteria

Inclusion criteria: Willingness to give informed consent fulfilling either of the following criteria : Advanced stage cervical cancer with extensive parametrial involvement, residual parametrical disease after EBRT, post hysterectomy gross residual disease, vaginal involvement.

Exclusion criteria

Exclusion criteria: Distorted pelvic anatomy, history of prior radiation, metastatic disease, uncontrolled medical comorbidities.

Design outcomes

Primary

Measure	Time frame
Local disease control rates by examination with 2 techniquesTimepoint: At baseline, 1 month, 2 months and 6 months after treatment	—

Secondary

Measure	Time frame
Acute and chronic toxicities with 2 techniquesTimepoint: 1,2 and 6 months	—

Countries

India

Contacts

Public ContactDr Vaishali Kataria

PGIMER, Chandigarh

drkapoor.r@gmail.com7087009396

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026